Search Result

Results for "

GGPP

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Apoptosis (3) Calcineurin (1) Calcium Channel (4) Endogenous Metabolite (5) Farnesyl Transferase (2) HMG-CoA Reductase (HMGCR) (1) Isotope-Labeled Compounds (2) Parasite (1) PI3K (1) Ras (3) TRP Channel (5)
By Research Areas:	Cancer (9) Infection (1) Inflammation/Immunology (6) Metabolic Disease (1) Neurological Disease (5)

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-113037C

Farnesyl pyrophosphate ammonium Farnesyl diphosphate ammonium	TRP Channel Endogenous Metabolite Calcium Channel	Neurological Disease Inflammation/Immunology Cancer
Farnesyl pyrophosphate (Farnesyl diphosphate) ammonium is a metabolic intermediate in the mevalonate (MVA) pathway. It is a TRP channel (TRPM2) agonist that triggers Ca2+ influx and cell death. Farnesyl pyrophosphate ammonium is a key branch substrate for cholesterol synthesis, ubiquinone synthesis, protein farnesylation, and geranylgeranyl pyrophosphate (GGPP) synthesis. Farnesyl pyrophosphate ammonium is used in research on cerebral ischemia, neurodegenerative diseases, pancreatic cancer, inflammation, and autoimmune diseases .

HY-U00145

Digeranyl bisphosphonate 3 Publications Verification DGBP	Ras	Inflammation/Immunology
Digeranyl bisphosphonate (DGBP) is a potent geranylgeranylpyrophosphate (GGPP) synthase inhibitor, which inhibits geranylgeranylation of Rac1.

HY-113037

(E/Z)-Farnesyl pyrophosphate (E/Z)-Farnesyl diphosphate	TRP Channel Endogenous Metabolite	Neurological Disease
(E/Z)-Farnesyl pyrophosphate ((E/Z)-Farnesyl diphosphate), a 15-carbon isoprenoid, is a metabolic intermediate of the mevalonate (MVA) pathway. (E/Z)-Farnesyl pyrophosphate is a TRPM2 (TRP Channel) agonist, activates TRPM2 opening for ion influx. (E/Z)-Farnesyl pyrophosphate is a key branch substrate for cholesterol synthesis, ubiquinones synthesis, protein farnesylation decoration, and geranyl-geranyl pyrophosphate (GGPP) synthesis .

HY-135700

Mevalonolactone	Calcineurin Ras HMG-CoA Reductase (HMGCR)	Metabolic Disease Inflammation/Immunology
Mevalonolactone is an intermediate metabolite in the eukaryotic mevalonate pathway, serving as the stable δ-lactone form of mevalonate with oral activity. Mevalonolactone exhibits binding affinity for ZNF384 (K_a = 12.6 μM) and inhibitory activity against aconitase (aconitase). Mevalonolactone promotes the nuclear localization of ZNF384 and enhances its binding to the *GGPPS* promoter. Mevalonolactone induces insulin resistance, disrupts glucose and lipid metabolism, enhances the isoprenylation of K-Ras, and inhibits the activation of the insulin signaling pathway. Mevalonolactone inhibits polypeptide synthesis of HMG-CoA reductase in isolated rat hepatocytes, promotes its degradation, and reduces its enzymatic activity. Mevalonolactone impairs mitochondrial function in rat brains. Mevalonolactone promotes the development of metabolically unhealthy obesity. Mevalonolactone can be used in research related to metabolically abnormal obesity, mevalonic aciduria, HMGCR-related limb-girdle myopathy, and statin-induced myopathy .

HY-113037CS

Farnesyl pyrophosphate-d2 triammonium Farnesyl diphosphate-d2 triammonium	Isotope-Labeled Compounds TRP Channel Endogenous Metabolite Calcium Channel	Neurological Disease Inflammation/Immunology Cancer
Farnesyl pyrophosphate-d₂ (Farnesyl diphosphate-d₂) triammonium is a deuterium labeled Farnesyl pyrophosphate triammonium (HY-113037C). Farnesyl pyrophosphate ammonium is a metabolic intermediate in the mevalonate (MVA) pathway. It is a TRP channel (TRPM2) agonist that triggers Ca2+ influx and cell death. Farnesyl pyrophosphate ammonium is a key branch substrate for cholesterol synthesis, ubiquinone synthesis, protein farnesylation, and geranylgeranyl pyrophosphate (GGPP) synthesis. Farnesyl pyrophosphate ammonium is used in research on cerebral ischemia, neurodegenerative diseases, pancreatic cancer, inflammation, and autoimmune diseases.

HY-113037B

Farnesyl pyrophosphate Farnesyl diphosphate	TRP Channel Endogenous Metabolite Calcium Channel	Neurological Disease Inflammation/Immunology Cancer
Farnesyl pyrophosphate is a metabolic intermediate in the mevalonate (MVA) pathway. It is a TRP channel (TRPM2) agonist that triggers Ca2+ influx and cell death. Farnesyl pyrophosphate is a key branch substrate for cholesterol synthesis, ubiquinone synthesis, protein farnesylation, and geranylgeranyl pyrophosphate (GGPP) synthesis. Farnesyl pyrophosphate is used in research on cerebral ischemia, neurodegenerative diseases, pancreatic cancer, inflammation, and autoimmune diseases.

HY-113752

MMV019313	Parasite	Infection
MMV019313 is a potent, non-bisphosphonate inhibitor of farnesyl/geranylgeranyl diphosphate synthase (FPPS/GGPPS) with an IC₅₀ of 0.82 µM. MMV019313 has activity against P. falciparum (Parasite) .

HY-113037AS

Farnesyl pyrophosphate-d6 Farnesyl diphosphate-d₆	Isotope-Labeled Compounds TRP Channel Endogenous Metabolite Calcium Channel	Neurological Disease Inflammation/Immunology Cancer
Farnesyl pyrophosphate-d₆ (Farnesyl diphosphate-d₆) is a deuterium labeled Farnesyl pyrophosphate (HY-113037B). Farnesyl pyrophosphate is a metabolic intermediate in the mevalonate (MVA) pathway. It is a TRP channel (TRPM2) agonist that triggers Ca2+ influx and cell death. Farnesyl pyrophosphate is a key branch substrate for cholesterol synthesis, ubiquinone synthesis, protein farnesylation, and geranylgeranyl pyrophosphate (GGPP) synthesis. Farnesyl pyrophosphate is used in research on cerebral ischemia, neurodegenerative diseases, pancreatic cancer, inflammation, and autoimmune diseases.

HY-136829

BPH-675	Apoptosis	Others
BPH-675 is a large bisphosphonate inhibitor with long hydrophobic side chains and a potent and selective geranylgeranyl diphosphate synthase (GGPPS) inhibitor with an IC₅₀ of 0.71 μM. GGPPS inhibitor promotes HUVEC apoptosis .

HY-124723

Gerfelin	Farnesyl Transferase	Cancer
Gerfelin inhibits *geranylgeranyl diphosphate synthase (GGPP* synthase) activity with an IC₅₀** of 3.5 μg/mL .

HY-113869

BPH-628	Apoptosis PI3K Akt	Cancer
BPH-628 is an aromatic geranylgeranyl diphosphate synthase (GGPPS) inhibitor, with a pIC₅₀ of 6.1 .

HY-113793

BPH-742	Ras	Cancer
BPH-742 (compound 9) is a Geranylgeranyl diphosphate synthase inhibitor with IC₅₀ of 0.1 μM. BPH-742 has antitumor activity .

HY-126472

BPH252	Farnesyl Transferase	Cancer
BPH252 (Compound 4) is a geranylgeranyl diphosphate synthase inhibitor. BPH252 can be used in research on bisphosphonate-based anticancer inhibitors .

HY-186013

CML-07-119	Apoptosis	Cancer
CML-07-119 is a selective inhibitor of GGPP synthase (GGPPS) with an IC₅₀ of ~27 nM. CML-07-119 induces apoptosis and exhibits anticancer activity against acute myeloid leukemia (AML) cells, including those harbouring TP53 mutations. CML-07-119 inhibits tumor growth in an AML mouse xenograft model. CML-07-119 can be used for AML research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-113037C

Farnesyl pyrophosphate ammonium Farnesyl diphosphate ammonium	Natural Products Neurological Disease Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification	TRP Channel Endogenous Metabolite Calcium Channel
Farnesyl pyrophosphate (Farnesyl diphosphate) ammonium is a metabolic intermediate in the mevalonate (MVA) pathway. It is a TRP channel (TRPM2) agonist that triggers Ca2+ influx and cell death. Farnesyl pyrophosphate ammonium is a key branch substrate for cholesterol synthesis, ubiquinone synthesis, protein farnesylation, and geranylgeranyl pyrophosphate (GGPP) synthesis. Farnesyl pyrophosphate ammonium is used in research on cerebral ischemia, neurodegenerative diseases, pancreatic cancer, inflammation, and autoimmune diseases .

HY-113037

(E/Z)-Farnesyl pyrophosphate (E/Z)-Farnesyl diphosphate	Structural Classification Natural Products Human Gut Microbiota Metabolites Microorganisms Neurological Disease Classification of Application Fields Endogenous metabolite Disease Research Fields Source Classification	TRP Channel Endogenous Metabolite
(E/Z)-Farnesyl pyrophosphate ((E/Z)-Farnesyl diphosphate), a 15-carbon isoprenoid, is a metabolic intermediate of the mevalonate (MVA) pathway. (E/Z)-Farnesyl pyrophosphate is a TRPM2 (TRP Channel) agonist, activates TRPM2 opening for ion influx. (E/Z)-Farnesyl pyrophosphate is a key branch substrate for cholesterol synthesis, ubiquinones synthesis, protein farnesylation decoration, and geranyl-geranyl pyrophosphate (GGPP) synthesis .

HY-135700

Mevalonolactone	Structural Classification Microorganisms Other Phenylpropanoids Phenylpropanoids Source Classification	Calcineurin Ras HMG-CoA Reductase (HMGCR)
Mevalonolactone is an intermediate metabolite in the eukaryotic mevalonate pathway, serving as the stable δ-lactone form of mevalonate with oral activity. Mevalonolactone exhibits binding affinity for ZNF384 (K_a = 12.6 μM) and inhibitory activity against aconitase (aconitase). Mevalonolactone promotes the nuclear localization of ZNF384 and enhances its binding to the *GGPPS* promoter. Mevalonolactone induces insulin resistance, disrupts glucose and lipid metabolism, enhances the isoprenylation of K-Ras, and inhibits the activation of the insulin signaling pathway. Mevalonolactone inhibits polypeptide synthesis of HMG-CoA reductase in isolated rat hepatocytes, promotes its degradation, and reduces its enzymatic activity. Mevalonolactone impairs mitochondrial function in rat brains. Mevalonolactone promotes the development of metabolically unhealthy obesity. Mevalonolactone can be used in research related to metabolically abnormal obesity, mevalonic aciduria, HMGCR-related limb-girdle myopathy, and statin-induced myopathy .

HY-124723

Gerfelin	Microorganisms Antibiotics Other Antibiotics Source Classification	Farnesyl Transferase
Gerfelin inhibits *geranylgeranyl diphosphate synthase (GGPP* synthase) activity with an IC₅₀** of 3.5 μg/mL .

Species:	Human (2)
Tag:	His (2)
Source:	HEK293 (1) E. coli (1)

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P70224

	GGPS1 Protein, Human (His) rHuGeranylgeranyl pyrophosphate synthase/GGPS1, His; Geranylgeranyl Pyrophosphate Synthase; GGPP Synthase; GGPPSase; (2E; 6E)-Farnesyl Diphosphate Synthase; Dimethylallyltranstransferase; Farnesyl Diphosphate Synthase; Farnesyltranstransferase; Geranylgeranyl Diphosphate Synthase; Geranyltranstransferase; GGPS1	Human	E. coli
	The GGPS1 protein is responsible for catalyzing the trans-addition of three molecules of isopentenyl pyrophosphate (IPP) to dimethylallyl pyrophosphate (DMAPP) to synthesize geranylgeranyl pyrophosphate. This compound is an important precursor for the biosynthesis of carotenoids and geranylated proteins. GGPS1 Protein, Human (His) is the recombinant human-derived GGPS1 protein, expressed by E. coli , with N-6*His labeled tag.

HY-P702577

	GGPS1 Protein, Human (HEK293, His) rHuGeranylgeranyl pyrophosphate synthase/GGPS1, His; Geranylgeranyl Pyrophosphate Synthase; GGPP Synthase; GGPPSase; (2E; 6E)-Farnesyl Diphosphate Synthase; Dimethylallyltranstransferase; Farnesyl Diphosphate Synthase; Farnesyltranstransferase; Geranylgeranyl Diphosphate Synthase; Geranyltranstransferase; GGPS1	Human	HEK293
	The GGPS1 protein is responsible for catalyzing the trans-addition of three molecules of isopentenyl pyrophosphate (IPP) to dimethylallyl pyrophosphate (DMAPP) to synthesize geranylgeranyl pyrophosphate. This compound is an important precursor for the biosynthesis of carotenoids and geranylated proteins. GGPS1 Protein, Human (HEK293, His) is the recombinant human-derived GGPS1, expressed by HEK293, with C-His labeled tag. The total length of GGPS1 Protein, Human (HEK293, His) is 300 a.a..

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-113037CS

Farnesyl pyrophosphate-d2 triammonium
Farnesyl pyrophosphate-d₂ (Farnesyl diphosphate-d₂) triammonium is a deuterium labeled Farnesyl pyrophosphate triammonium (HY-113037C). Farnesyl pyrophosphate ammonium is a metabolic intermediate in the mevalonate (MVA) pathway. It is a TRP channel (TRPM2) agonist that triggers Ca2+ influx and cell death. Farnesyl pyrophosphate ammonium is a key branch substrate for cholesterol synthesis, ubiquinone synthesis, protein farnesylation, and geranylgeranyl pyrophosphate (GGPP) synthesis. Farnesyl pyrophosphate ammonium is used in research on cerebral ischemia, neurodegenerative diseases, pancreatic cancer, inflammation, and autoimmune diseases.

Farnesyl pyrophosphate-d2 triammonium

Farnesyl pyrophosphate-d₂ (Farnesyl diphosphate-d₂) triammonium is a deuterium labeled Farnesyl pyrophosphate triammonium (HY-113037C). Farnesyl pyrophosphate ammonium is a metabolic intermediate in the mevalonate (MVA) pathway. It is a TRP channel (TRPM2) agonist that triggers Ca2+ influx and cell death. Farnesyl pyrophosphate ammonium is a key branch substrate for cholesterol synthesis, ubiquinone synthesis, protein farnesylation, and geranylgeranyl pyrophosphate (GGPP) synthesis. Farnesyl pyrophosphate ammonium is used in research on cerebral ischemia, neurodegenerative diseases, pancreatic cancer, inflammation, and autoimmune diseases.

HY-113037AS

Farnesyl pyrophosphate-d6
Farnesyl pyrophosphate-d₆ (Farnesyl diphosphate-d₆) is a deuterium labeled Farnesyl pyrophosphate (HY-113037B). Farnesyl pyrophosphate is a metabolic intermediate in the mevalonate (MVA) pathway. It is a TRP channel (TRPM2) agonist that triggers Ca2+ influx and cell death. Farnesyl pyrophosphate is a key branch substrate for cholesterol synthesis, ubiquinone synthesis, protein farnesylation, and geranylgeranyl pyrophosphate (GGPP) synthesis. Farnesyl pyrophosphate is used in research on cerebral ischemia, neurodegenerative diseases, pancreatic cancer, inflammation, and autoimmune diseases.

Farnesyl pyrophosphate-d6

Farnesyl pyrophosphate-d₆ (Farnesyl diphosphate-d₆) is a deuterium labeled Farnesyl pyrophosphate (HY-113037B). Farnesyl pyrophosphate is a metabolic intermediate in the mevalonate (MVA) pathway. It is a TRP channel (TRPM2) agonist that triggers Ca2+ influx and cell death. Farnesyl pyrophosphate is a key branch substrate for cholesterol synthesis, ubiquinone synthesis, protein farnesylation, and geranylgeranyl pyrophosphate (GGPP) synthesis. Farnesyl pyrophosphate is used in research on cerebral ischemia, neurodegenerative diseases, pancreatic cancer, inflammation, and autoimmune diseases.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks